Sep 09, 2021 / 12:50PM GMT
Navann Ty - Citigroup Inc., Research Division - Director
Good morning, everyone. Welcome to day 2 of our conference and to Alkermes fireside chat. I'm Navann Ty, I cover Spec Pharma at Citi, and I have the pleasure having Blair Jackson, EVP and COO of Alkermes; and Iain Brown, SVP and CFO. Maybe Blair and Iain, if you could start with a short introduction to Alkermes, it will be very helpful and then I could go to Q&A.
Blair C. Jackson - Alkermes plc - Executive VP & COO
Sure. We'd be happy to. Thanks for the introduction. And maybe before I start, I'll just highlight that we will be making forward-looking statements, and so I encourage everyone to review our regulatory filings for a more full risk disclosure. But we really appreciate you having us at the conference. It's a little shocking that it's already September. It's been a crazy year for us. We've got a lot going on at the company. And it's really been a year focused on execution and execution across multiple lanes of the business. On the commercial side, driving the performance of our products,
Alkermes Plc at Citi BioPharma Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers